FOLH1 and prostate cancer: Small molecule, radio-labeled PSMA inhibitor-based radiopharmaceuticals, such as [68Ga]Ga-PSMA-11 and [177Lu]Lu-PSMA-617, have played significant roles in the tremendous progress nuclear medicine has experienced in the diagnosis and therapy of prostate cancer [17,18,19,20].